BRIEF—ExeVir makes new senior appointments

Infectious disease specialist ExeVir Bio has appointed Viki Bockstal as chief scientific officer and Caroline Sagaert as head of operations, with Jean-Philippe Bultot taking over as head of finance.

ExeVir said Dr Bockstal has “extensive experience” in infectious diseases, immunology, and viral vaccine technology from her previous R&D work at Janssen.

Formerly a senior finance manager at Bone Therapeutics, Mr Bultot has been ExeVir’s controller and financial operations lead since October 2021.

Chief executive Torsten Mummenbrauer said: “We have come so far since 2020, including securing $20 million in major grants, closing a $50 million Series A, raising a $27.5 million venture debt with the EIB and completing a Phase Ia and Ib clinical study.”

Fiona du Monceau will step down as the current chief operating officer and chief finance officer and will become an observer on the board.